These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR). Odani S; Komori Y; Gejyo F Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113 [TBL] [Abstract][Full Text] [Related]
3. Nephrotoxic potential of Bence Jones proteins. Solomon A; Weiss DT; Kattine AA N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132 [TBL] [Abstract][Full Text] [Related]
4. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues. Foss GS; Nilsen R; Cornwell GC; Husby G; Sletten K Scand J Immunol; 1998 Apr; 47(4):348-54. PubMed ID: 9600316 [TBL] [Abstract][Full Text] [Related]
5. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. Harris DL; King E; Ramsland PA; Edmundson AB J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557 [TBL] [Abstract][Full Text] [Related]
6. Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Sikkink LA; Ramirez-Alvarado M Amyloid; 2008 Mar; 15(1):29-39. PubMed ID: 18266119 [TBL] [Abstract][Full Text] [Related]
7. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients. Blancas-Mejía LM; Martin EB; Williams A; Wall JS; Ramirez-Alvarado M Biophys Chem; 2017 Nov; 230():89-98. PubMed ID: 28916410 [TBL] [Abstract][Full Text] [Related]
8. Tetramer Bence Jones protein in the immunoproliferative diseases. Angioimmunoblastic lymphadenopathy, primary amyloidosis, and multiple myeloma. Kosaka M; Iishi Y; Okagawa K; Saito S; Sugihara J; Muto Y Am J Clin Pathol; 1989 Jun; 91(6):639-46. PubMed ID: 2499179 [TBL] [Abstract][Full Text] [Related]
9. Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis. Klafki HW; Kratzin HD; Pick AI; Eckart K; Karas M; Hilschmann N Biochemistry; 1992 Mar; 31(12):3265-72. PubMed ID: 1554711 [TBL] [Abstract][Full Text] [Related]
10. Bence Jones proteins and light chains of immunoglobulins. XIII. Effect of elastase-like and chymotrypsin-like neutral proteases derived from human granulocytes on Bence Jones proteins. Solomon A; Schmidt W; Havemann K J Immunol; 1976 Sep; 117(3):1010-4. PubMed ID: 60445 [TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin D myeloma and amyloidosis: immunochemical and structural studies of Bence Jones and amyloid fibrillar proteins. White GC; Jacobson RJ; Binder RA; Linke RP; Glenner GG Blood; 1975 Nov; 46(5):713-22. PubMed ID: 809071 [TBL] [Abstract][Full Text] [Related]
12. Amino-terminal identity of co-existent amyloid and non-amyloid immunoglobulin kappa light chain deposits. A human disease to study alterations of protein conformation. Kaplan B; Vidal R; Kumar A; Ghiso J; Frangione B; Gallo G Clin Exp Immunol; 1997 Dec; 110(3):472-8. PubMed ID: 9409653 [TBL] [Abstract][Full Text] [Related]
13. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276 [TBL] [Abstract][Full Text] [Related]
14. [A case of multiple myeloma with alternating paraprotein; non-secretory myeloma (IgG-kappa) converted to nonproducing myeloma, and finally to secretory myeloma (BJ-lambda) (author's transl)]. Fujii H; Kanoh T Nihon Naika Gakkai Zasshi; 1981 Nov; 70(11):1553-61. PubMed ID: 6801164 [No Abstract] [Full Text] [Related]
15. Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis. Terry WD; Page DL; Kimura S; Isobe T; Osserman EF; Glenner GG J Clin Invest; 1973 May; 52(5):1276-81. PubMed ID: 4700495 [TBL] [Abstract][Full Text] [Related]
16. Constant region of a kappa III immunoglobulin light chain as a major AL-amyloid protein. Engvig JP; Olsen KE; Gislefoss RE; Sletten K; Wahlström O; Westermark P Scand J Immunol; 1998 Jul; 48(1):92-8. PubMed ID: 9714416 [TBL] [Abstract][Full Text] [Related]
17. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723 [TBL] [Abstract][Full Text] [Related]
18. Bence-Jones protein-type myeloma with amyloid myopathy presenting as amyloidomas and extensive amyloid deposits in the muscularis propria: a rapidly fatal autopsy case. Ikezawa Y; Oka K; Nagayama R; Okubo Y; Yonekawa N; Hirai F; Ebihara I; Mori N Int J Surg Pathol; 2012 Feb; 20(1):83-8. PubMed ID: 21632635 [TBL] [Abstract][Full Text] [Related]
19. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains. Davern S; Murphy CL; O'Neill H; Wall JS; Weiss DT; Solomon A Biochim Biophys Acta; 2011 Jan; 1812(1):32-40. PubMed ID: 20692337 [TBL] [Abstract][Full Text] [Related]
20. Induction in mice of human light-chain-associated amyloidosis. Solomon A; Weiss DT; Pepys MB Am J Pathol; 1992 Mar; 140(3):629-37. PubMed ID: 1546744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]